Anti-LRAT [M34-P1F10]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 151869 |
Applications | ELISA IHC IF WB |
Antigen/Gene or Protein Targets | Lecithin Retinol Acyltransferase (LRAT) |
Reactivity | Human |
Relevance | LRAT is significantly overexpressed in colorectal cancer and significantly associated with prognosis. |
Host | Mouse |
Immunogen | Peptide Sequence - RDQRSVLASA (amino acids 190 -199) |
Positive Control | ELISA- Peptide immunogenWestern Blot- Overexpression lysate Immunofluorescence- Hela Cells IHC- Human colon carcinoma |
Subclass | IgG1 |
Recommended Growing Conditions | Dulbecco’s media containing 20% Fetal Bovine serum (DH20) prepared as follows (for final volume of 300ml: 237ml DMEM + 60 ml Fetal Bovine Serum plus 3ml L-Glutamine + 3ml of Penicillin -Streptomycin. |
Strain | Balb/c |
Research Area | Cell Signaling & Signal Transduction, Metabolism, Neurobiology |
References: 2 entries
Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.
The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.
Europe PMC ID: 24608339
Add a reference
References: 2 entries
Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.
The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.
Add a reference